Test Code:
10 unstained sections of tumour and a corresponding H&E-stained histological section, OR
1 paraffin block of tumour
Background
A proportion of spindle cell/sclerosing rhabdomyosarcomas harbour a recurrent somatic point mutation of the MYOD1 gene c.365T>G p.Leu122Arg resulting in the mutated MyoD1 protein having MYC-like properties. MYOD1-mutated spindle cell/sclerosing RMS have an aggressive clinical course.
Purpose of test
The test identifies the specific MYOD1 point mutation c.365T>G p.Leu122Arg (p.L122R) by Sanger sequencing.
Expected test result
MYOD1 p.L122R mutation detected/not detected.
Caveats
DNA integrity and concentration must meet assay requirements. Low tumour content (<50%) may result in a false negative result.
Proficiency testing
Alternative performance assessment programme.
Reference
Kohsaka S et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations
12 Apr 2024 8:00 AM
Update of specimen requirement, test name, additional information and editorial edit
23 Apr 2025 4:00 PM
Change test title
12/03/2018 12:00 AM
{0}
{1}
Subscribe to our mailing list to get the updates to your email inbox...
